ADAR1 Capital acquires 1,000 InMed common shares worth $1,555

ADAR1 Capital Management, a 10% owner of InMed Pharmaceuticals, purchased 1,000 common shares at $1.56 each, totaling $1,555. This transaction increased ADAR1's indirect holdings to 801,000 shares. Daniel Schneeberger, the manager of ADAR1, is listed as the reporting person for this disclosure filed with the SEC.

InMed Pharmaceuticals disclosed a purchase of 1,000 common shares at $1.56 by 10% owner ADAR1 Capital Management. * Indirect holdings rose to 801,000 common shares following the buy. * ADAR1 manager Daniel Schneeberger was listed as a reporting person. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001940272-26-000010), on July 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

INM